Cytoprotective and antisecretory activity of a ranitidine-zinc complex.
The effects of a ranitidine-zinc complex and ranitidine alone were compared in three different experimental models (pyloric ligation, ethanol and indomethacin) of gastric ulceration in the rat. In the pyloric ligation model, the ranitidine-zinc complex (50, 100 and 150 mg/kg p.o.) showed antiulcerogenic activity similar to that observed with equimolar doses of ranitidine (35, 70 and 105 mg/kg p.o.). Both the ranitidine-zinc complex and ranitidine significantly reduced (p < 0.05) gastric acid secretion in a dose-dependent manner. The protective effect of the ranitidine-zinc complex (100 and 150 mg/kg p.o.) against gastric damage developing after p.o. administration of absolute ethanol or indomethacin was enhanced (p < 0.05) with respect to that obtained with equimolar doses of ranitidine (70 and 105 mg/kg p.o.). The presence of zinc in the ranitidine-zinc complex does not interfere with the antisecretory effects of ranitidine on the gastric mucosa, while it confers an additional cytoprotective action to the final compound.
Conchillo
A
A
Pharmacology Department, Laboratorios Viñas, S.A., Barcelona, Spain.
Mola
C
C
Navarro
C
C
Bravo
L
L
Bulbena
O
O
D000818:Animals; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D000431:Ethanol; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D007213:Indomethacin; D008297:Male; D011899:Ranitidine / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013276:Stomach Ulcer / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D015032:Zinc / Q000494:pharmacology / Q000627:therapeutic use*
D004338:Drug Combinations; D000431:Ethanol; D011899:Ranitidine; D015032:Zinc; D007213:Indomethacin